FDA Move Opens Door to Biosimilar Insulins, Other Biologics
In a historic shift, FDA transitions regulatory pathway for insulin and other biologics, meaning products deemed ‘biosimilar’ will be able to compete more easily with brands, in theory lowering prices. Medscape Medical News …read more